Inhibition of Focal Adhesion Kinase Overcomes Resistance of Mantle Cell Lymphoma to Ibrutinib in the Bone Marrow Microenvironment

Overview

Journal Haematologica

Specialty Hematology

Date 2017 Oct 29

PMID 29079592

Citations 36

Authors

Martina Rudelius

Mathias Tillmann Rosenfeldt

Ellen Leich

Hilka Rauert-Wunderlich

Antonio Giovanni Solimando

Andreas Beilhack

German Ott

Andreas Rosenwald

Affiliations

Soon will be listed here.

Abstract

Mantle cell lymphoma and other lymphoma subtypes often spread to the bone marrow, and stromal interactions mediated by focal adhesion kinase frequently enhance survival and drug resistance of the lymphoma cells. To study the role of focal adhesion kinase in mantle cell lymphoma, immunohistochemistry of primary cases and functional analysis of mantle cell lymphoma cell lines and primary mantle cell lymphoma cells co-cultured with bone marrow stromal cells (BMSC) using small molecule inhibitors and RNAi-based focal adhesion kinase silencing was performed. We showed that focal adhesion kinase is highly expressed in bone marrow infiltrates of mantle cell lymphoma and in mantle cell lymphoma cell lines. Stroma-mediated activation of focal adhesion kinase led to activation of multiple kinases (AKT, p42/44 and NF-κB), that are important for prosurvival and proliferation signaling. Interestingly, RNAi-based focal adhesion kinase silencing or inhibition with small molecule inhibitors (FAKi) resulted in blockage of targeted cell invasion and induced apoptosis by inactivation of multiple signaling cascades, including the classic and alternative NF-κB pathway. In addition, the combined treatment of ibrutinib and FAKi was highly synergistic, and ibrutinib resistance of mantle cell lymphoma could be overcome. These data demonstrate that focal adhesion kinase is important for stroma-mediated survival and drug resistance in mantle cell lymphoma, providing indications for a targeted therapeutic strategy.

Citing Articles

Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence.

Capasso G, Mouawad N, Castronuovo M, Ruggeri E, Visentin A, Trentin L Front Oncol. 2024; 14:1446723.

PMID: 39281374 PMC: 11392731. DOI: 10.3389/fonc.2024.1446723.

Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.

Nylund P, Nikkarinen A, Ek S, Glimelius I Front Immunol. 2024; 15:1373269.

PMID: 38566987 PMC: 10985169. DOI: 10.3389/fimmu.2024.1373269.

Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview.

Argentiero A, Andriano A, Marziliano D, Desantis V Hematol Rep. 2024; 16(1):164-178.

PMID: 38534887 PMC: 10970354. DOI: 10.3390/hematolrep16010017.

PTH and the Regulation of Mesenchymal Cells within the Bone Marrow Niche.

Liu H, Liu L, Rosen C Cells. 2024; 13(5.

PMID: 38474370 PMC: 10930661. DOI: 10.3390/cells13050406.

Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.

Jain N, Mamgain M, Chowdhury S, Jindal U, Sharma I, Sehgal L J Hematol Oncol. 2023; 16(1):99.

PMID: 37626420 PMC: 10463717. DOI: 10.1186/s13045-023-01496-4.

References

Zhang H, Chen Z, Neelapu S, Romaguera J, McCarty N . Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment. Oncotarget. 2016; 7(12):14350-65. PMC: 4924720. DOI: 10.18632/oncotarget.7320. View

Dreyling M, Ferrero S . The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?. Haematologica. 2016; 101(2):104-14. PMC: 4938333. DOI: 10.3324/haematol.2014.119115. View

Mitra S, Schlaepfer D . Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006; 18(5):516-23. DOI: 10.1016/j.ceb.2006.08.011. View

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16. PMC: 4513941. DOI: 10.1056/NEJMoa1306220. View

Medina D, Goodell L, Glod J, Gelinas C, Rabson A, Strair R . Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica. 2012; 97(8):1255-63. PMC: 3409825. DOI: 10.3324/haematol.2011.040659. View

Itoh S, Maeda T, Shimada M, Aishima S, Shirabe K, Tanaka S . Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res. 2004; 10(8):2812-7. DOI: 10.1158/1078-0432.ccr-1046-03. View

Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P . Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014; 4(9):1022-35. PMC: 4155003. DOI: 10.1158/2159-8290.CD-14-0098. View

Balsas P, Palomero J, Eguileor A, Rodriguez M, Vegliante M, Planas-Rigol E . SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017; 130(4):501-513. DOI: 10.1182/blood-2017-04-776740. View

Koliaraki V, Pasparakis M, Kollias G . IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med. 2015; 212(13):2235-51. PMC: 4683996. DOI: 10.1084/jem.20150542. View

10.

Wang M, Blum K, Martin P, Goy A, Auer R, Kahl B . Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126(6):739-45. PMC: 4528064. DOI: 10.1182/blood-2015-03-635326. View

11.

Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C . Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood. 2011; 118(18):4930-4. DOI: 10.1182/blood-2011-06-359166. View

12.

Xargay-Torrent S, Lopez-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A . Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. Clin Cancer Res. 2012; 19(3):586-97. DOI: 10.1158/1078-0432.CCR-12-1935. View

13.

Wu X, Liu Y, Wang G, Xu X, Cai Y, Wang H . Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-κB activation. Sci Rep. 2016; 6:21420. PMC: 4759824. DOI: 10.1038/srep21420. View

14.

You D, Xin J, Volk A, Wei W, Schmidt R, Scurti G . FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells. Cell Rep. 2015; 10(12):2055-68. PMC: 7001526. DOI: 10.1016/j.celrep.2015.02.056. View

15.

Jakubikova J, Cholujova D, Hideshima T, Gronesova P, Soltysova A, Harada T . A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016; 7(47):77326-77341. PMC: 5357212. DOI: 10.18632/oncotarget.12643. View

16.

Rahal R, Frick M, Romero R, Korn J, Kridel R, Chan F . Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2013; 20(1):87-92. DOI: 10.1038/nm.3435. View

17.

Jares P, Colomer D, Campo E . Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012; 122(10):3416-23. PMC: 3461905. DOI: 10.1172/JCI61272. View

18.

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

19.

Burger J, Ghia P, Rosenwald A, Caligaris-Cappio F . The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009; 114(16):3367-75. PMC: 4969052. DOI: 10.1182/blood-2009-06-225326. View

20.

Yu X, Han Q, Wen Z, Ma L, Gao J, Zhou G . Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett. 2012; 322(2):185-94. DOI: 10.1016/j.canlet.2012.03.004. View